BeyondSpring Inc.

NASDAQ:BYSI

Biotechnology

Healthcare
$1.25 +1.58%

+$0.03 today

Market cap
$51.40M
Beta
0.42
P/E (TTM)
-8.7
EPS (TTM)
-$0.19
52W Low $1.18High $3.28

Volume 0.01M

Average 0.02M

BYSI Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

BeyondSpring Inc.NASDAQ: BYSI

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$19K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$19K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$19K or moves back toward the trailing-twelve-month quarterly average of -$4.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19K— QoQ
Last fiscal yearDec 2025
-$87K— YoY
LTMMar 2026
-$19K+96.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(87K) USD
Year-over-year change
—

Gross Profit vs competitors

How BYSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +96.2% is the 2nd highest of 7, against a peer median of +5.8%.
BYSI Competitors
Gross Profit for BYSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.7M USD-14.6%+7.9%97.0%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$11.07M CAD+26.1%+7.2%60.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3M USD+337.0%—76.2%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
BYSIBeyondSpring Inc.LTM Mar 2026-$19K USD+96.2%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$211K USD———
BMEABiomea Fusion, Inc.LTM Mar 2026-$593K USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026-$22.33M USD-82.6%—11754.7%
Peer median (excluding BYSI) —+5.8%+7.6%86.6%

Competitors are the stored peer set for BYSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.35M1.35M000
Cost of Revenue00302K087K
Gross Profit1.35M1.35M(302K)0(87K)
Gross Margin100.0%100.0%———
Research & Development36.89M25.58M7.27M2.64M4.39M
Selling, General & Admin30.7M13.01M7.51M6.11M4.56M
Operating Expenses67.59M38.59M14.78M8.75M8.86M
Depreciation & Amortization61K1.14M302K285K87K
EBITDA(64.49M)(34.96M)(13.62M)(8.48M)(8.54M)
EBITDA Margin-4773.5%-2587.4%———
Operating Income(66.24M)(37.24M)(15.08M)(8.75M)(8.95M)
Operating Margin-4903.0%-2756.4%———
Interest Income98K195K421K59K78K
Interest Expense87K17K000
Other Income / Expenses1.6M1.12M1.16M(15K)320K
Income Before Tax(64.64M)(36.12M)(13.92M)(8.77M)(8.63M)
Pre-Tax Margin-4784.5%-2673.4%———
Income Tax Expense3.57M163K92K96K90K
Net Income(64.18M)(33.28M)(21.03M)(11.12M)(7.99M)
Net Margin-4750.5%-2463.3%———
EPS (Basic)(1.64)(0.85)(0.54)(0.28)(0.20)
EPS (Diluted)(1.64)(0.85)(0.54)(0.28)(0.20)
Weighted Avg Shares39.02M39.09M39M39.73M40.41M
Weighted Avg Shares (Diluted)39.02M39.09M39M39.73M40.41M

BeyondSpring Inc.

NASDAQ:BYSI

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.